Cargando…

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib

Itacitinib is a novel, selective, Janus kinase 1 inhibitor in development for treatment of graft‐versus‐host disease. The objective of this study was to assess pharmacokinetics and safety of 300‐mg itacitinib dosed in participants with normal renal function (n = 10), severe renal impairment (n = 8),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srinivas, Nithya, Barbour, April M., Epstein, Noam, Zhou, Gongfu, Petusky, Susan, Xun, Zhinyin, Yuska, Brad, Marbury, Thomas, Chen, Xuejun, Yeleswaram, Swamy, Punwani, Naresh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	NON COVID RELATED ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496630/ https://www.ncbi.nlm.nih.gov/pubmed/32149388 http://dx.doi.org/10.1002/jcph.1601

Ejemplares similares

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
por: Li, Jia, et al.
Publicado: (2020)

Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment
por: Schultze‐Mosgau, Marcus‐Hillert, et al.
Publicado: (2020)

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
por: Ji, Tao, et al.
Publicado: (2022)

Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
por: Ji, Tao, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study
por: Vanhoutte, Frédéric, et al.
Publicado: (2020)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection
por: Deng, Rong, et al.
Publicado: (2020)

Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation
por: Renaud, Lionel, et al.
Publicado: (2020)

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling
por: Posada, Maria M., et al.
Publicado: (2020)

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
por: Provenzano, Robert, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule‐1 (MAdCAM‐1), in Patients With Ulcerative Colitis or Crohn's Disease
por: Wang, Yi, et al.
Publicado: (2020)

A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam
por: VanLandingham, Kevan E., et al.
Publicado: (2020)

Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis
por: Purohit, Vivek, et al.
Publicado: (2020)

Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects
por: Tellone, Valeria, et al.
Publicado: (2020)

Exploring the Relationship Between Morphine Concentration and Oversedation in Children After Cardiac Surgery
por: Valkenburg, Abraham J., et al.
Publicado: (2020)

Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users
por: Schippers, Frank, et al.
Publicado: (2020)

A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft‐versus‐host disease
por: Pratta, Michael, et al.
Publicado: (2022)

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
por: Gong, Xiaohua, et al.
Publicado: (2021)

P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL)
por: Kadia, T., et al.
Publicado: (2022)

Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies
por: Gong, Xiaohua, et al.
Publicado: (2021)

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors
por: Beatty, Gregory L., et al.
Publicado: (2018)

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2018)

Delayed presentation and sub-optimal outcomes of pediatric patients with acute appendicitis during the COVID-19 pandemic
por: Gerall, Claire D., et al.
Publicado: (2021)

TMPRSS2: Potential Biomarker for COVID‐19 Outcomes
por: Strope, Jonathan D., et al.
Publicado: (2020)

Limiting hospital resources for acute appendicitis in children: Lessons learned from the U.S. epicenter of the COVID-19 pandemic()()()
por: Kvasnovsky, Charlotte L, et al.
Publicado: (2021)

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
por: Naing, Aung, et al.
Publicado: (2022)

Correction: Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
Publicado: (2022)

Transitioning from hospital to home with non-invasive ventilation: who benefits? Results of a cohort study
por: Fox, Benjamin Daniel, et al.
Publicado: (2022)

Mortality and the Use of Antithrombotic Therapies Among Nursing Home Residents with COVID‐19
por: Brouns, Steffie H., et al.
Publicado: (2020)

Stemming the Tide of COVID‐19 Infections in Massachusetts Nursing Homes
por: Lipsitz, Lewis A., et al.
Publicado: (2020)

Impact of COVID-19 on Work-Related Musculoskeletal Disorders for Cardiac Sonographers
por: Mazal, Jill, et al.
Publicado: (2021)

Frailty and comorbidity in predicting community COVID‐19 mortality in the U.K. Biobank: The effect of sampling
por: Mak, Jonathan K. L., et al.
Publicado: (2021)

Fisetin for COVID‐19 in skilled nursing facilities: Senolytic trials in the COVID era
por: Verdoorn, Brandon P., et al.
Publicado: (2021)

Application of the Haddon matrix to COVID‐19 prevention and containment in nursing homes
por: Fritch, William M., et al.
Publicado: (2021)

Research on the front lines of COVID‐19 in hospitalized older adults with dementia
por: Sinvani, Liron, et al.
Publicado: (2021)

Lessons learned from frontline skilled nursing facility staff regarding COVID‐19 vaccine hesitancy
por: Berry, Sarah D., et al.
Publicado: (2021)

Management and outcomes of a COVID‐19 outbreak in a nursing home with predominantly Black residents
por: Beiting, Kimberly J., et al.
Publicado: (2021)

Reframing aging during COVID‐19: Familial role‐based framing of older adults linked to decreased ageism
por: Ng, Reuben, et al.
Publicado: (2021)

A systematic review of long‐term care facility characteristics associated with COVID‐19 outcomes
por: Konetzka, R. Tamara, et al.
Publicado: (2021)

Challenges and opportunities in conducting research with older adults with dementia during COVID‐19 and beyond
por: Sharma, Rashmi K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k31dqb4h7uermmds4vkj5nv15a